大动脉硬与阿尔茨海默病:梅丁的联系
Filippos Triposkiadis1,2, Andrew Xanthopoulos1,2, Harisios Boudoulas3
1European University Cyprus, 1516 Nicosia, Cyprus.
Biomolecules
|August 28, 2025
概括
大动脉硬化与衰老有关,可能会导致阿尔茨海默病 (AD) 通过蛋白质片段. 医学促进粉样蛋白聚合和炎症,可能为阿尔茨海默病提供新的治疗点.
科学领域:
- 老年学
- 神经科学
- 心血管科学
背景情况:
- 老化导致大动脉硬化 (AoSt),降低弹性,增加认知能力下降的风险,包括阿尔茨海默病 (AD).
- 从MFG-E8衍生而来的Medin与AoSt与AD的联系有关.
- 在老年人中,梅丁形成大动脉中部粉样蛋白 (AMA),导致血管炎症和化.
研究的目的:
- 探索梅丁作为与年龄有关的大动脉硬化和阿尔茨海默病之间的关键联系的假设.
- 调查梅丁在促进脑血管功能障碍和神经炎症中的作用.
主要方法:
- 对医学在血管和大脑病理方面的新兴证据的审查.
- 对梅丁与粉样β (Aβ) 的相互作用及其对粉样病理的贡献的分析.
- 医学对内皮功能,氧化应激和质细胞激活的影响的研究.
主要成果:
- 梅丁聚合在AMA中,导致血管炎症,化和动脉弹性降低.
- 医学增强了Aβ聚合 (交叉播种),导致脑血管功能障碍和神经炎症.
- 梅丁可以促进炎症,加剧认知衰退.
结论:
- 梅丁可以作为连接大动脉硬化与阿尔茨海默病的桥梁.
- 梅丁在血管和神经炎症中的作用表明它是阿尔茨海默病的潜在新疗法目标.
- 需要进一步实验和临床验证梅丁在阿尔茨海默病中的作用.
相关概念视频
Alzheimer's Disease: Overview
666
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
666
Alzheimer's Disease: Treatment
260
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
260
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
38
Atherosclerosis is a progressive disorder that leads to the thickening and narrowing of arterial walls due to plaque buildup. This condition can cause various symptoms depending on the arteries affected:Coronary Artery Disease (CAD): This condition affects the coronary arteries and may lead to chest pain (angina), shortness of breath (dyspnea), heart attacks, and other heart disease symptoms.Cerebrovascular Disease: This affects blood flow to the brain, causing transient ischemic attacks (TIAs)...
38
Atherosclerosis I: Introduction
76
Atherosclerosis is a progressive disorder characterized by the buildup of plaques on the arterial inner wall, causing them to narrow and harden over time. These plaques comprise lipids, calcium, blood components, carbohydrates, and fibrous tissue. The process primarily affects the intima of large and medium-sized arteries, reducing blood flow in any artery.Etiology and risk factorsThe cause of atherosclerosis is multifactorial, involving a complex interplay among endothelial injury, lipid...
76
Aortic Regurgitation II: Clinical Features and Diagnostic Tests
52
Aortic valve regurgitation (AR) occurs when the aortic valve fails to close properly, allowing blood to flow backward from the aorta into the left ventricle. This backflow can result in two distinct clinical presentations: acute and chronic AR, each characterized by its own set of symptoms and physical findings.Acute Aortic RegurgitationAcute AR presents with a sudden onset of severe symptoms. Patients typically experience profound dyspnea (shortness of breath), chest pain, and signs of left...
52
Atherosclerosis III: Management
33
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
33


